MRSN - NASDAQ

Mersana Therapeutics, Inc.

MRSN·NASDAQ

$29.08

+0.0000%

HealthcareBiotechnology

Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen development candidate. It has a strategic research and development partnerships with Merck KGaA and Asana BioSciences, LLC for the development of ADC product candidates utilizing Fleximer. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$145.36M

EPS-14.1200

P/E Ratio-2.53

Earnings Date03/02/2026

mrsn

Research Development Expenses

Last Annual Value

73.02M

3-Year CAGR

-18%

5-Year CAGR

10-Year CAGR

13%

Adjust for Inflation

Mersana Therapeutics, Inc. Competitors Analysis of research-development-expenses

MRSN · NASDAQ

Company	research-development-expenses	CAGR 3Y	CAGR 5Y	CAGR 10Y
Mersana Therapeutics, Inc. NASDAQ:MRSN	73.02M	-21.0%	-11.2%	8.6%
Aligos Therapeutics, Inc. NASDAQ:ALGS	69.45M	-1.7%	-7.8%	N/A
Kezar Life Sciences, Inc. NASDAQ:KZR	33.76M	-26.7%	-2.8%	16.4%
Xilio Therapeutics, Inc. NASDAQ:XLO	56.04M	2.4%	1.8%	N/A
OnKure Therapeutics, Inc. NASDAQ:OKUR	48.26M	14.5%	11.4%	N/A
X4 Pharmaceuticals, Inc. NASDAQ:XFOR	72.72M	0.3%	8.3%	15.1%
BioAtla, Inc. NASDAQ:BCAB	63.09M	-15.3%	1.6%	N/A
INmune Bio, Inc. NASDAQ:INMB	33.17M	17.8%	10.1%	78.4%

Mersana Therapeutics, Inc. Fair Value Envelope

MRSN · NASDAQ

Our analysis suggests that MRSN has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $29.08, this represents a potential HIDDEN relative to our calculated worth for Mersana Therapeutics, Inc..

HIDDEN

Intrinsic Value

Current Price: $29.08

Related Guides

Blog Categories

Continue your MRSN research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.